OcuTerra Therapeutics

0 followers


OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

Industries

Employees

1-10

Links

Org chart

David J. Tanzer
Chief Medical Officer
Susannah Sinozich
Senior Clinical Program Director

Board & advisors

Robert Ruffolo
Board Member
Robin Steele
Board Member
Barbara Ryan
Board Member
David S. Boyer
Advisory Board Member
Jeffrey S. Heier
Advisory Board Member
Peter Kaiser
Advisory Board Member
Sheri Rowen
Advisory Board Member
Paul Karpecki
Advisory Board Member
Richard Lindstrom
Advisory Board Member